Estimated effect of pneumococcal conjugate vaccination on invasive pneumococcal disease and associated mortality, Denmark 2000-2005

Zitta B. Harboe*, Palle Valentiner-Branth, Thomas L. Benfield, Jens Jørgen Christensen, Thomas Hjuler, Margit Kaltoft, Karen A. Krogfelt, Lotte Lambertsen, Helle B. Konradsen

*Corresponding author af dette arbejde

    Publikation: Bidrag til tidsskriftArtikelForskningpeer review

    Abstract

    In order to provide an estimation of the direct and indirect benefits of pneumococcal vaccination with three protein-conjugate pneumococcal vaccines (PCV) we described the epidemiology and mortality from invasive pneumococcal disease (IPD) in Denmark between 2000 and 2005. Approximately 1080 cases were registered annually during the period. The overall incidence of IPD increased significantly, from 15.4 cases per 100,000 population in 2000 to 20.7 cases per 100,000 in 2005 (p < 0.01), mainly due to an increase in bacteraemia cases. The serotype coverage in children under 5 years varied from 64% to 91% depending on the PCV used. The mean mortality proportion after IPD was 18%, with approximately 190 deaths annually. One to two deaths among children younger than 5 years and approximately 50 deaths related to IPD caused by vaccine serotypes among older age groups could be prevented annually by introducing a PCV. Approximately 70% of all deaths occurred in adults over 65 years, underlining the need for protection against IPD in this age group.

    OriginalsprogEngelsk
    Sider (fra-til)3765-3771
    Antal sider7
    TidsskriftVaccine
    Vol/bind26
    Udgave nummer29-30
    DOI
    StatusUdgivet - 4 jul. 2008

    Fingeraftryk

    Udforsk hvilke forskningsemner 'Estimated effect of pneumococcal conjugate vaccination on invasive pneumococcal disease and associated mortality, Denmark 2000-2005' indeholder.

    Citationsformater